Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > CUDC-101

CUDC-101

CUDC-101 structure

CUDC-101 

structure
  • CAS No:

    1012054-59-9

  • Formula:

    C24H26N4O4

  • Chemical Name:

    CUDC-101

  • Synonyms:

    CUDC101;CUDC-101;7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide;HeptanaMide, 7-[[4-[(3-ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxy-;7-[[4-[(3-Ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxyheptanaMide;7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamideCUDC-101;7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide;CUDC-101, >=98%

  • Categories:

    Biochemical Engineering  >  Inhibitors

Description

CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively.


CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.

CUDC-101 Basic Attributes

434.48764

434.195404

-0

1A7Y9MP123

DTXSID00143784

Characteristics

106

4

white

1.28

174-177℃

1.638

DMSO: soluble

-20°C

Safety Information

NONH for all modes of transport

3

Drug Information

7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide

CUDC-101 Use and Manufacturing

Methods of Manufacturing

7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (Compound 12); The title compound 12 was prepared as a grey solid (100 mg, 41percent) from compound 0113-12 (250 mg, 0.56 mmol) using a procedure similar to that described for compound 1 (Example 1): m.p. 171.8177.2° C. (dec); LCMS: 435 [M+1]The freshly prepared hydroxylamine solution (30 mL, 110 mmol) was placed in 50 mL flask. Compound 0408-12 (4.93 g, 11.0 mmol) was added to this solution and stirred at 25Step 8h'. Step 8h'. 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (Compound 12); The freshly prepared hydroxylamine solution (30 mL, 110 mmol) was placed in 50 mL flask. Compound 0408-12 (4.93 g, 11.0 mmol) was added to this solution and stirred at 25° C. for 24 hours. After reaction the mixture was neutralized with acetic acid, and the resulting precipitate was isolated, washed with water, and dried to give the title compound 12 as a white solid (3.99 g, 83.6percent): mp 174.1177.2° C. LCMS: 435 [M+1]Step 8b. 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (Compound 12); The title compound 12 was prepared as a grey solid (100 mg, 41percent) from compound 0113-12 (250 mg, 0.56 mmol) using a procedure similar to that described for compound 1 (Example 1): m.p. 171.8177.2° C. (dec); LCMS: 435 [M+1]

Uses

CUDC-101 is a potent multi-acting HDAC (histone deacetylase), EGFR (epidermal growth factor receptor), and HER2 ( human epidermal growth factor receptor 2) inhibitor for the treatment of cancer.

Computed Properties

Molecular Weight:434.5
XLogP3:4
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:12
Exact Mass:434.19540532
Monoisotopic Mass:434.19540532
Topological Polar Surface Area:106
Heavy Atom Count:32
Complexity:624
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of CUDC-101

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.